Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (77)

« Back to Publications

Early lymph node T follicular helper cell signalling hub drives influenza vaccine response in an ancestrally diverse cohort.

Siu JHY. et al, (2025), EBioMedicine, 122

Gonorrhoea vaccination strategies should take into account all at risk and the potential for severe sequelae in women.

Freeman-Romilly N. et al, (2025), BMJ, 390

Two distinct subpopulations of human stem-like memory T cells exhibit complementary roles in self-renewal and clonal longevity.

Koftori D. et al, (2025), PLoS Biol, 23

Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth

Pollock K. et al, (2024), EBioMedicine

Early regional lymph node activation drives influenza vaccine responses in an ancestrally diverse cohort

Siu JHY. et al, (2024)

Multi-site Ultrasound-guided Fine Needle Aspiration to Study Cells and Soluble Factors From Human Lymph Nodes.

Al-Diwani A. et al, (2024), Curr Protoc, 4

ntibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib.

Liu Z. et al, (2024), J Crohns Colitis, 18, 560 - 569

phase I double-blind trial investigating trachoma vaccine regimens using the Chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02)

Pollock K., (2024), The Lancet Infectious Diseases

Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine.

Thwaites RS. et al, (2023), Nat Commun, 14

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.

Liu Z. et al, (2023), EClinicalMedicine, 64

Characterization of Rare Spontaneous Human Immunodeficiency Virus Viral Controllers Attending a National United Kingdom Clinical Service Using a Combination of Serology and Molecular Diagnostic Assays.

Khan M. et al, (2023), Open Forum Infect Dis, 10

Characterisation of Rare Spontaneous HIV Viral Controllers Attending a National UK Clinical Service Using a Combination of Serology and Molecular Diagnostic Assays

Khan M. et al, (2023)

Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.

Writing Committee for the REMAP-CAP Investigators . et al, (2023), JAMA, 329, 1183 - 1196

The effect of TRV027 on coagulation in COVID-19: A pilot randomized, placebo-controlled trial.

Robbins AJ. et al, (2023), Br J Clin Pharmacol, 89, 1495 - 1501

Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.

Liu Z. et al, (2023), Gastroenterology, 164, 300 - 303.e3

Load More

1
2
3
4
5
6